Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread because drugs have been approved only for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Phosphodiesterase type 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are most commonly prescribed as first-line treatment for PAH, and the more-efficacious prostacyclin therapies are used in later lines. Branded therapies dominate the PAH treatment algorithm, and combination therapy is common. Adempas is the only therapy approved for CTEPH. The lack of therapies approved for PH and the high morbidity and mortality associated with it make the disease a highly lucrative therapy market.
Geographies: EU5: France, Germany, Italy, Spain, United Kingdom
Primary Research: Survey of 250 cardiologists / pulmonologists in the EU5
Key Drugs Covered: Uptravi, Opsumit, Remodulin, Adempas, sildenafil, tadalafil, iloprost, epoprostenol
Key Insights Provided